Abstract
The adjunctive use of simvastatin for patients with ventilator-associated pneumonia (VAP) was associated with an increase in 28-day mortality, although not statistically significant.
You are on the new improved site. You can view the old site in view-only mode here until June 27, 2026
Select search scope: search across all journals or within the current journal
The adjunctive use of simvastatin for patients with ventilator-associated pneumonia (VAP) was associated with an increase in 28-day mortality, although not statistically significant.